A Phase IB/III Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat, An Investigational Agent, Or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT04224493

Study #:
STUDY00146199

Start Date:
Mar 29, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04224493

View Complete Trial Details & Eligibility at ClinicalTrials.gov